CASI Pharmaceuticals Inc
casipharmaceuticals.comWhat Do They Do?
Develops an antibody medicine for organ transplant rejection and autoimmune diseases, and manages other drug candidates and medicines.
How Do They Make Money?
CASI sells medicines to distributors; imported products are sold when handed to the carrier the distributor appoints, and locally made products when distributors accept them.
20-F for FY2025, filed May 15, 2026
$20.7M
-
20-F for FY2025, filed May 15, 2026
$20.7M ↗
Who Are Their Customers?
CASI used third-party distributors for approved medicines: CRPCGIT for EVOMELA® and CNMC for FOLOTYN® (sales of which ceased after its China license expired). CASI was also appointed a non-exclusive distributor of YuTuo® in China.
20-F for FY2025, filed May 15, 2026
20-F for FY2025, filed May 15, 2026
All of the Company’s EVOMELA® sales were generated from a single customer, CRPCGIT in China. For the years ended December 31, 2025, 2024…View ↗
Do Revenues Turn Into Profits?
No. It lost $48.1M in FY2025.
20-F for FY2025, filed May 15, 2026
−$45MView ↗
20-F for FY2025, filed May 15, 2026
−$48.1MView ↗
20-F for FY2025, filed May 15, 2026
−$20.8MView ↗
How Are They Changing?
Shrinking. Revenue fell 31% in 4 years, from $30.2M in FY2021 to $20.7M in FY2025, about 9% a year.
From China operations to global drug development
The older report described an integrated business centered on acquiring, developing and commercializing products for China; the latest describes a clinical-stage company focused on global development of an antibody candidate after selling China operations and regional rights.
20-F for FY2022, filed Apr 26, 2023 20-F for FY2025, filed May 15, 2026We have built a fully integrated, world class biopharmaceutical company dedicated to the successful development and commercialization of…View ↗
The Company has historically built and operated a fully integrated biopharmaceutical organization dedicated to the development and…View ↗
Who Do They Compete With?
Competes with Xi’An Libang Pharmaceuticals, Sichuan Huiyu Pharmaceutical, Biogen, Takeda, Keymed Biosciences, and Timberlyne Therapeutics
20-F for FY2025, filed May 15, 2026In September 2022, Xi’An Libang Pharmaceuticals Co., Ltd. introduced the first domestically produced injectable melphalan formulated with…View ↗
Loading...
